Skip to content

Impact of Erector Spinae Plane Block on Systemic Immune-inflammation Index

Impact of Erector Spinae Plane Block on Systemic Immune-inflammation Index in Breast-conserving Surgery: A Retrospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07137702
Enrollment
127
Registered
2025-08-22
Start date
2025-07-15
Completion date
2025-08-15
Last updated
2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Conserving Surgery, Erector Spinae Plane Block, Systemic Immune-inflammatory Index

Keywords

systemic immune-inflammatory index, erector spinae plane block, breast conserving surgery

Brief summary

The primary objective of the study is to determine whether there is a relationship between postoperative SII and erector spinae plane block application. If data emerges indicating a more suppressed inflammatory response in patients undergoing block, widespread use of this block in the specified patient group would reflect the clinical significance of the study. The searches did not uncover any studies investigating the effects of trunk blocks, such as erector spinae plane block, on postoperative systemic inflammatory response, indicating that this study could make a significant contribution to the literature.

Detailed description

Because the study will be conducted retrospectively, it carries no potential risks. If it can be demonstrated that blocking has a suppressive effect on the inflammatory response, the main expected benefit of the study is its widespread use to improve postoperative outcomes.

Interventions

PROCEDUREErector Spinae Plane Block

A standardized perioperative care management protocol is applied for all breast-conserving surgery procedures in our department. All patients are informed about ESPB and offered its application preoperatively. Patients who accept the procedure receive ESPB (preoperatively, in the sitting position, at the level of ipsilateral T4 vertebra, USG guided, out-of-plane approach) while those who refuse are subjected to routine intravenous analgesia protocols. All blocks were performed by an anesthesiologist experienced in the application of truncal blocks and 20 cc 0.5% bupivacaine (within the safe dose range for all patients to be used according to their weight) are injected and its spread is visualized under USG.

Sponsors

Taner Abdullah
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

ASA score ≤ 3, breast-conversing surgery, age \> 18 -

Exclusion criteria

ASA score \> 3, reoperation, surgical wound infection, chemotherapy in less than 2 weeks, bening lesions \-

Design outcomes

Primary

MeasureTime frameDescription
systemic immune-inflammation index7 days after surgeryPlatelet count × Neutrophil count / Lymphocyte count

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026